Helicobacter infection
Drug research and approvals for helicobacter infection: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 59 studies of helicobacter infection are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 59
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Safety of Vonoprazan-Amoxicillin Dual Therapy Versus Concomitant Quadruple Therapy for H. Pylori EradicationNCT07924098 · Phase 4 · Ignacio Moratorio · starts Aug 5, 2026
- Keverprazan-Minocycline Dual Therapy of Different Durations Versus Bismuth Quadruple Therapy for Helicobacter Pylori…NCT07904429 · Phase 3 · Nanjing First Hospital, Nanjing Medical University · starts Jul 15, 2026
- Efficacy and Safety of Linarazen Gluconate Capsules Combined With Amoxicillin (Dual-Drug Therapy) Versus…NCT07897994 · Phase 4 · Yongquan Shi · starts Oct 1, 2026
- Feasibility and Performance of FFPE qPCR for Detection of Clarithromycin Resistance in Helicobacter PyloriNCT07821294 · Not reported · Clinique Bizet · starts Sep 10, 2026
- The Prevalence and the Pathophysiological Role of Non-Helicobacter Pylori Helicobacter Spp. in Well-defined Gastric…NCT07770126 · Not reported · Universiteit Antwerpen · starts Feb 24, 2025
- A Prospective Cohort Study on Endoscopic Features of Upper Gastrointestinal Tract at High Altitude (Zaduo County)NCT07755384 · Not reported · Jilin University · starts Dec 1, 2025
- Helicobacter Pylori Infection Status and Pathological Features for Predicting Gastric Cancer Biological Behavior and…NCT07724496 · Not reported · Chinese PLA General Hospital · starts Jan 1, 2024
- Study on the Effect of Fecal Microbiota Transplantation on Eradication of Refractory Helicobacter Pylori InfectionNCT07704255 · Phase 4 · Sichuan Provincial People's Hospital · starts Jul 20, 2026
- Impact of Eradication Therapy on Helicobacter Pylori Infection With Chronic Obstructive Pulmonary Disease:NCT07574879 · Phase 1 · Zagazig University · starts Mar 1, 2026
How its trials ended
197 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 26 whose ending is known, 62% met their primary endpoint, 8% missed it and 31% stopped early.
- Status unknown6935%
- Completed, result not reported6533%
- Ongoing3719%
- Met its primary endpoint168%
- Stopped: other or unclear74%
- Missed its primary endpoint21%
- Stopped: enrollment or feasibility11%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA